Shenzhen Edge Medical Co., Ltd. (Edge Medical) disclosed a share repurchase completed on 9 October 2026, acquiring 255,900 H shares on the Hong Kong Stock Exchange for a total consideration of HK$8.39 million. The purchase price ranged between HK$32.54 and HK$33.00 per share, translating into a volume-weighted average cost of HK$32.77.

Following the transaction, Edge Medical’s issued share capital (excluding treasury shares) fell 0.08% to 324.98 million shares, while its treasury-share balance increased to 2.78 million shares. The company’s total issued share count remains unchanged at 327.76 million shares, as the repurchased shares are being held in treasury rather than cancelled.

The buyback forms part of a broader mandate approved by shareholders on 25 June 2026, which authorises repurchases of up to 32.61 million shares. Including the latest transaction, Edge Medical has repurchased 1.17 million shares under this mandate, representing 0.36% of the company’s issued share base at the time the authorisation was granted.

In accordance with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 8 November 2026.